Reata Pharma buys back rights from AbbVie for Nrf2 activators

11 October 2019

US biotech Reata Pharmaceuticals (Nasdaq: RETA) closed up 13% at $85.98 yesterday after it revealed it was reacquiring development, manufacturing and commercialization rights concerning its proprietary Nrf2 activator product platform originally licensed to AbbVie (NYSE: ABBV) for territories outside of the USA with respect to bardoxolone methyl and worldwide with respect to omaveloxolone and other next-generation Nrf2 activators.

As a result, Reata now owns exclusive, worldwide rights to these products, excluding certain Asian markets for bardoxolone which are licensed to Kyowa Kirin (TYO: 4151).

Both drugs target the transcription factor NRF2 and have pivotal trials, dubbed CARDINAL (bardoxolone, for patients with Alport syndrome) and MOXIe (omaveloxolone, for the rare genetic disease Friedreich's ataxia), set to give top-line results by the end of 2019.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK